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Objective—We conducted a baseline study of human papillomavirus (HPV) type prevalence in 
invasive cervical cancers (ICC) using data from seven cancer registries (CR) in the US. Cases 
were diagnosed between 1994 and 2005, before the implementation of the HPV vaccines.
Materials and Methods—CRs from Florida, Kentucky, Louisiana, Michigan, Hawaii, Iowa and 
Los Angeles, California identified eligible ICC cases, and obtained sections from representative 
blocks of archived tumor specimens for DNA extraction. All extracts were assayed by Linear 
Array and if inadequate or HPV negative, re-tested with INNO-LiPA Genotype test. Clinical and 
demographic factors were obtained from the CRs and merged with the HPV typing data to analyze 
factors associated with different types and with HPV negativity.
Results—A total of 777 ICCs were included in this analysis, with broad geographic, age and race 
distribution. Overall, HPV was detected in 91% of cases, including 51% HPV16, 16% HPV18 
(HPV16 negative), and 24% other oncogenic and rare types. After HPV16 and 18, the most 
common types were 45, 33, 31, 35 and 52. Older age and non-squamous histology were associated 
with HPV negative typing.
Conclusions—This study provides baseline pre-vaccine HPV types for post-vaccine ICC 
surveillance in the future. HPV16 and/or 18 were found in 67% of ICCs, indicating the potential 
for vaccines to prevent a significant number of cervical cancers.
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Background
Invasive cervical cancer (ICC) is the third most common cancer among females worldwide, 
with an estimated 530,000 new cases in 2008.1 In the same year, in the United States (US) 
there were 12,410 new cases diagnosed and 4,008 deaths attributable to ICC.2 While 
incidence and mortality rates in the US have declined in recent decades due to the 
widespread use of the Papanicolaou (Pap) test and improved treatment, there are still 
disparities by race and geography.3, 4
Human papillomavirus (HPV) is an established risk factor for developing ICC.5–7 While 
infection with HPV is common, and usually does not result in ICC, persistent infection with 
high-risk, or oncogenic, types of HPV increases a woman’s risk of developing cancer. 
International prevalence studies estimate that about 70% of ICCs are attributed to HPV16 
and HPV18.8–11 A meta-analysis of 85 studies worldwide showed the overall detection rate 
for HPV in ICC was similar in all regions (83–89%); HPV16 was the predominant type in 
squamous cell carcinoma (46–63%) followed by HPV18 (10–14%), while for 
adenocarcinoma and adenosquamous carcinoma the predominant type was HPV18 (37–
41%) followed by HPV16 (26–36%).9
There are currently two HPV vaccines available which protect against HPV16 and 18, 
targeted for girls before the onset of sexual activity (and HPV exposure), with catch-up 
vaccine approved to age 26.12 It will be at least 10–30 years before the first vaccinated 
female cohorts reach the ages at greatest risk for cancer precursors such as cervical 
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intraepithelial neoplasia 3 (CIN-3) and adenocarcinoma in situ (AIS), and ICC.13 It is of 
great public health importance to monitor the impact of these vaccines on the rates of ICC, 
as well as any changes in the HPV types responsible for future cases of ICC that might occur 
as a result of widespread use of the vaccines.14 The high-quality cancer registries in the US, 
such as those included in the National Program of Cancer Registries (NPCR) and the 
Surveillance, Epidemiology, and End Results (SEER) Program, provide the infrastructure 
for a sentinel surveillance system to monitor these potential changes on a long-term basis.13
The burden of HPV-associated cancers in the US was recently assessed using 1998–2003 
data from NPCR and the SEER Program, providing baseline rates and geographic 
distribution of ICC in the US in the pre-vaccine era.4 Since HPV typing of cancers is not 
performed as part of clinical care, this information is not available to cancer registries. 
Recent studies have determined type-specific prevalence of HPV in ICC cases in various 
populations in the US,15–19 but this is the first registry-based, multi-state assessment of HPV 
in ICC, prior to the approval of HPV vaccines.
Methods
NPCR registries in Kentucky, Louisiana, Michigan and Florida (Kentucky, Louisiana and 
Detroit, MI are also part of the SEER Program) requested stored tissue samples from a 
simple random statewide sample of women diagnosed with ICC during 2004–2005. For 
Florida, the sample included three counties in the southeast part of the state (Palm Beach, 
Broward, Miami-Dade). Three SEER residual tissue repositories (RTR) that store tissue 
specimens that would otherwise be discarded, submitted samples from ICC cases: Los 
Angeles County, California, 1994–1999; Iowa statewide, 1994–1999; Hawaii statewide, 
2000–2004.
All participating registries followed the same protocol for identifying and submitting the 
formalin-fixed paraffin-embedded (FFPE) tissue samples. Eligible cases had to be state 
residents of the participating registry and have a histologically-confirmed ICC (ICD-O-3 site 
codes C53.0, C53.1, C53.8, C53.9 and behavior code 3) diagnosed during the study years 
described above. Study coordinators in Kentucky, Louisiana, Michigan and Florida 
requested participation of hospitals and pathology laboratories where tissue blocks for 
eligible cases were stored. The criteria for selection of a representative diagnostic block 
from each case included the highest ratio of viable tumor to normal tissue and the best 
preservation (favoring use of biopsy rather than resection specimen). Participating 
laboratories prepared the samples according to the study protocol. In some cases, a central 
laboratory prepared the samples, and then the paraffin tissue blocks were returned to the 
donating facility. For the SEER RTRs, a laboratory at each site prepared the tissue samples. 
Materials for submitting and shipping the specimens were provided by CDC, and specimens 
were sent directly to the CDC for analysis. Selected demographic and clinical data from 
each registry were linked with HPV typing results to form a complete record.
CDC received IRB approval for the study, and each participating registry completed an IRB 
review with its own institution. In addition, some hospitals and pathology laboratories 
required an IRB review before participating.
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Blocks were cut using precautions to prevent polymerase chain reaction (PCR) 
contamination between cases, including single-use disposable microtome blades, cleaning 
microtome between samples, and direct transfer of sections for PCR from microtome to 
sterile tubes using clean single-use applicator. The first and last sections were stained with 
Hematoxylin and Eosin (H&E). Intervening sections were transferred into 2 ml conical 
screw cap tubes with tether cap, one 10-micron section or two 5-mciron sections per tube 
(Simport, Beloeil, Canada).
H&E sections were reviewed by a study pathologist to confirm that tumor was present. 
Samples that did not have representative material were not processed. For confirmed 
samples, DNA was extracted with the Chemagic Viral NA/gDNA Kit special (chemagen 
USA, Worcester MA) as previously described.20 Briefly, sections were heated for 20 min at 
120°C in 180 µl tissue lysis buffer, then incubated with Proteinase K overnight at 65°C and 
then purified using Chemagic MSM1 (chemagen USA). The DNA was eluted in a final 
volume of 100 µl.
All DNA extracts were tested with the Linear Array HPV Genotyping Test (LA, Roche 
Diagnostics, Indianapolis, IN). The test was performed according to the manufacturer’s 
protocol except for a template volume of 10 µl in the PCR reaction and the use of Beeblot 
instrument (Bee Robotics, Caernarfon, UK) for automated hybridization and washing of the 
reverse line blot. The LA detects 37 HPV types (6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42, 45, 
51, XR(52), 53, 54, 55, 56, 58, 59, 61, 62, 64, 66, 67, 68, 69, 70, 71, 72, 73, 81, 82, 83, 84, 
89, IS39). Samples positive for the XR probe that were also positive for HPV33, 35 and 58 
required further evaluation to confirm or exclude the presence of HPV52. An HPV52 
quantitative PCR assay was used to determine the status of HPV52 in these cases.21
Samples with negative or inadequate LA results were re-tested with the INNO-LiPA HPV 
Genotyping Assay (LiPA, Innogenetics, Gent, Belgium) following the manufacturer’s 
specifications. LiPA detects 29 HPV types (6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 43, 44, 45, 
51, 52, 53, 54, 56, 58, 59, 66, 68, 69, 70, 71, 73, 74, 81, 82). Samples failing both assays 
were considered inadequate and excluded from analysis (N=9). H&E slides of negative 
samples were reviewed to see if sampling or preservation could have contributed to false 
negative results.
Statistical Analysis
The descriptive analysis presented here includes tabulation of HPV typing results by 
registry, race, age, histology, stage, grade, and urban/rural residence, and distribution of 
HPV types alone and in combinations. Statistical analysis was conducted using Stata 10 
software.22
We used the hierarchical categories for HPV types as suggested by Wheeler et al.15 with 
HPV16 as the most oncogenic type: HPV16 positive; HPV18 positive, HPV16 negative; 
HPV16 and HPV18 negative, positive for other oncogenic HPV types (31, 33, 35, 39, 45, 
51, 52, 56, 58, 59, 66, 68); negative for major oncogenic HPV types, but positive for other 
HPV types, both oncogenic and non-oncogenic; negative for all HPV. Rates of positive and 
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negative results were compared by race, age, histology, stage and grade using bivariate 
analysis and as well as logistic regression to elucidate factors associated with HPV 
negativity.
Results
Tissue samples for 786 cases of ICC were eligible for testing, 777 of which (98.9%) were 
adequate for evaluation. Selected demographic variables are presented by registry in Table 
1. Overall, 53% of cases were non-Hispanic white; however, the racial/ethnic distribution 
varied considerably by state, as expected. Most cases were non-Hispanic white in Iowa, 
Kentucky and Michigan, while in Louisiana the cases were distributed evenly between non-
Hispanic white and non-Hispanic black. Florida and Los Angeles had the largest proportion 
of Hispanic cases, and in Hawaii, 68% were Asian-Pacific Islander. Overall, less than half of 
the cases were aged 50 years and older, and almost one-third were among young women 
under age 40. The majority of the cases resided in urban counties. Because of their 
classification as urban counties, Los Angeles County and the three-county area in Florida 
did not contribute any cases from a rural residence.
Overall, HPV16 was detected in 51% of cases, followed by HPV18 (with HPV16 negative) 
which was detected in 16% of the cases (Table 1). In addition, 21% of cases were negative 
for HPV16 and 18 but positive for other oncogenic types, 3.2% were positive for other HPV 
types, and 9.4% tested negative for HPV. Among those positive for HPV16 and/or HPV18, 
9.5% were also positive for other HPV types (data not shown).
Table 2 presents the HPV categories by selected demographic and clinical variables for the 
seven registries combined. HPV16 was detected in over half the women in the younger age 
groups but was less common in older women. Overall, HPV18 was detected in 16% of 
cases; however, it varied greatly among the age groups with young women under age 30 
having the highest proportion and women aged 70 and older having the lowest. Women aged 
70 and older were less likely to be positive for HPV16 and HPV18, and more likely to be 
positive for other oncogenic HPV types. The majority of squamous cell carcinomas were 
positive for HPV16 (56%), followed by 25% which were negative for HPV16 and 18 but 
positive for other oncogenic types. For adenocarcinomas, 36% were HPV16 positive, 
followed by 32% HPV18 positive, while 20% were negative for HPV. Most cases in the 
histologic category of “All other” were HPV16 positive (46%), followed by 32% which 
were negative for HPV. About half of the local, regional and distant cases were positive for 
HPV16, but HPV types varied considerably for the remaining half in each category. A 
higher percentage of cases in the local (21%) and regional (22%) stages were positive for 
types other than HPV16 and 18, compared to distant stage (12%).
Negative results for oncogenic HPV types were more common among women who were 
older and non-Hispanic white, and among tumors that were adenocarcinomas, and cancers 
that were more advanced stage and grade. When all these variables were included in a 
logistic model, only age and histology were found to be statistically significant independent 
predictors: older women were more likely than younger to have HPV negative results 
(OR=3.2 for 50–69 and OR=5.8 for 70+, compared with 40–49 years old); and 
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adenocarcinomas (OR=5.1) and “all others” (OR=6.3) were more likely to be HPV negative 
than squamous tumors.
The H&E slides of the 73 samples with negative results were reviewed to see if sampling or 
preservation could have contributed to false negative results. Only seven were limited by 
extremely small foci of tumor (9.6%) and all appeared to be adequately preserved. Nearly 
60% were adeno- or adenosquamous carcinomas that could not be distinguished 
histologically from endometrial cancers.
HPV types (single and combinations) by the hierarchical categories are shown in Table 3. 
Single-type HPV16 was found in 44% of tumor samples, and single-type HPV18 was found 
in 15%. With respect to the current vaccine coverage, 67% of cases were positive for 
HPV16 and/or 18; 7% of these also had additional HPV types detected. Among cases 
negative for HPV16 and 18, the five types with the highest frequency were HPV45 (5.3%), 
HPV33 (3.2%), HPV31 (1.9%), HPV35 (1.9%) and HPV52 (1.8%). We also examined HPV 
types among just HPV-positive samples (N=704), as in a study of 17 countries in Europe,23 
and found 342 (49%) were HPV16 only; 116 (16%) were HPV18 only; 182 (26%) were 
other single HPV types; 64 (9%) were multiple types (of which 10, or 1.4%, were HPV16 
and 18).
Discussion
In our registry-based study including seven geographical regions of the US, 67% of ICC 
were positive for HPV16 and/or 18, and 24% for other types. This is generally in agreement 
with other studies and meta-analyses that have found that about 70% of cervical cancers can 
be attributed to HPV16 and 18.8–11 In our study, HPV16, HPV18 and HPV45 were most 
commonly detected, similar to studies from New Mexico and Washington.15, 16 We found 
substantial differences in HPV types by histology, with squamous cell having the highest 
percentage of HPV16, but the lowest percentage of HPV18.
Our results are also consistent with a joint analysis of two recent multi-center studies in 
Europe, which included 17 countries and about 2,900 cases of ICC.23 However, direct 
comparisons are hard to make as they only presented an analysis of HPV-positive cases; 
among those with single HPV infections (80% of their HPV-positive cases), 79% were 
either HPV16 or HPV18, which is similar to our results if we exclude the negatives (73%, 
analysis not shown). Among the 704 HPV-positive cases in our analysis, 9% had multiple 
HPV types (2 or more), compared with 17.4% in the European study, but because of how the 
data were presented we cannot analyze what factors may account for this difference.
Although it has been accepted that HPV is a necessary factor in the causal pathway to ICC,5 
HPV is not always detected in tumor specimens from women diagnosed with ICC. Overall, 
we found 91% of cases tested positive for HPV, which is consistent with other studies, and 
similar to results of a recent meta-analysis including over 40,000 ICC cases worldwide 
where 89% tested positive for HPV,24 and another meta-analysis of 1,503 cases from studies 
dating from 1994 to 2007.25 We observed substantial variation in the proportion of negative 
HPV results across the variables considered, but only older age and adenocarcinomas 
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remained significant in the multivariate logistic regression. Similar findings for age and 
histology were reported in a large study in Spain.26 Nearly 60% of the HPV negative cases 
could not be distinguished from endometrial primaries on the basis of histology alone. 
Attributing lower-uterine segment endometrial to endocervical primaries may be one 
explanation for HPV negative results. As endometrial cancers are more likely to occur in 
older women, the higher prevalence of HPV negative tumors in older age groups and with 
non-squamous histology raises the possibility that some tumors were of non-cervical origin. 
False negative results due to limitations of HPV detection and typing methods cannot be 
ruled out.
With respect to the reach of the current vaccines, our results suggest that 67% of the cases 
could potentially be covered, as they were positive for HPV16 and/or 18 either alone or in 
combination with other types. A nonavalent vaccine is being developed which will cover 
HPV31, 33, 45, 52 and 58 in addition to HPV16, 18, 6 and 11. Based on the distribution of 
HPV types in our study, the coverage of such a vaccine would increase another 18%.
This study demonstrates the effectiveness of using a registry-based approach to sample and 
determine HPV type distribution in cervical cancer. The strength of this approach is that the 
data for the submitted cases were very complete except for stage, and seven different regions 
of the US were included. Not all cases could be included as not all facilities agreed to 
participate and some tissue blocks could not be located or did not have an adequate sample. 
Another limitation was the restriction in lifestyle or behavioral variables available in the data 
routinely and uniformly collected by the cancer registries, such as smoking, co-morbidities, 
number of sexual partners and other risky health factors that would allow a more 
comprehensive characterization of the factors associated with the different HPV types.
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Table 3
HPV type distribution among invasive cervical cancer cases by hierarchical group
HPV Types Number Percent
HPV16 positive 395 50.8
  HPV16 342 44.0
  HPV16, 18 10 1.4
  HPV16, 33 6 0.8
  HPV16, 45 5 0.6
  HPV16, 58 5 0.6
  HPV16, 52 4 0.5
  HPV16, 59 4 0.5
  HPV16, 31 2 0.3
  HPV16, 39 2 0.3
  HPV16, 56 2 0.3
  HPV16, 18, 31 1 0.1
  HPV16, 18, 33 1 0.1
  HPV16, 18, 33, 45 1 0.1
  HPV16, 18, 45, 52 1 0.1
  HPV16, 18, 51, 55, 73 1 0.1
  HPV16, 26 1 0.1
  HPV16, 35, 52, 55, 71, 72, 83 1 0.1
  HPV16, 42 1 0.1
  HPV16, 51, 68 1 0.1
  HPV16, 54 1 0.1
  HPV16, 61 1 0.1
  HPV16, 66 1 0.1
  HPV16, is39 1 0.1
HPV18 positive, HPV16 negative 122 15.7
  HPV18 116 14.9
  HPV18, 33 1 0.1
  HPV18, 35, 70, 73 1 0.1
  HPV18, 45 1 0.1
  HPV18, 52 1 0.1
  HPV18, 70 1 0.1
  HPV18, 72 1 0.1
HPV16/18 negative, positive for other oncogenic types 162 20.9
  HPV45 41 5.3
  HPV33 25 3.2
  HPV31 15 1.9
  HPV35 15 1.9
  HPV52 14 1.8
  HPV39 13 1.7













Hopenhayn et al. Page 15
HPV Types Number Percent
  HPV58 13 1.7
  HPV56 6 0.8
  HPV59 6 0.8
  HPV68 4 0.5
  HPV51 3 0.4
  HPV66 2 0.3
  HPV33, 58 2 0.3
  HPV39, 45 1 0.1
  HPV53, 56 1 0.1
  HPV11, 31 1 0.1
Other rare HPV typesa 25 3.2
Negative for HPV 73 9.4
a
Includes 6,11,26,40,54,62,67,69,70,73,82, is 39 and four cases detected but not typed.
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